Pathogenesis of osteopenia/osteoporosis induced by highly active anti-retroviral therapy for AIDS

Academic Article


  • The advent of highly active anti-retroviral therapy (HAART) has dramatically decreased the rate of AIDS-related mortality and significantly extended the life span of patients with AIDS. A variety of metabolic side effects are associated with these therapies, one of which is metabolic bone disease. A higher prevalence of osteopenia and osteoporosis in HIV-infected patients receiving anti-retroviral therapy than in patients not on therapy has now been reported in several studies. Several factors have been demonstrated to influence HIV-associated decreases in bone mineral density (BMD), including administration of nucleoside reverse transcriptase inhibitors (NRTIs). In this article, discussion will focus on the molecular pathogenesis and treatment of HAART-associated osteopenia and osteoporosis. © 2006 New York Academy of Sciences.
  • Digital Object Identifier (doi)

    Author List

  • Pan G; Yang Z; Ballinger SW; McDonald JM
  • Start Page

  • 297
  • End Page

  • 308
  • Volume

  • 1068
  • Issue

  • 1